Shorter antibiotic courses in the immunocompromised: the impossible dream?

Area of Science:

• Infectious Diseases
• Pharmacology
• Immunocompromised Host Management

Background:

• Shorter antibiotic courses show promise for bacterial infections, but immunocompromised patients are often excluded.
• Benefits of shorter courses include reduced antibiotic toxicity, Clostridioides difficile infection, drug resistance, and microbiome disruption.
• Immunocompromised populations, such as solid organ transplant recipients and neutropenic fever patients, could benefit significantly.

Purpose of the Study:

• To review existing literature on shorter antibiotic courses in immunocompromised patients.
• Specifically focusing on solid organ transplant recipients and neutropenic fever syndromes.
• To evaluate the efficacy and safety of shortened antibiotic durations in these vulnerable groups.

Main Methods:

• Literature search conducted across major databases: PubMed, Embase, and MEDLINE.
• Included relevant clinical guidelines documents in the search.
• Critical review of retrospective and randomized studies assessing shorter antibiotic courses.

Main Results:

• Retrospective studies in organ transplant recipients show similar clinical outcomes with shorter antibiotic courses.
• High- and low-risk neutropenic fever patients have been studied, with some randomized trials.
• Clinical improvement-guided shorter courses led to fewer antibiotic days and comparable fever recurrence and mortality rates.

Conclusions:

• Shorter antibiotic courses are a viable option for immunocompromised patients with bacterial infections.
• Organ transplant recipients and patients with neutropenic fever syndromes warrant further investigation in clinical trials.
• Randomized controlled trials are crucial to confirm the efficacy and safety of shorter antibiotic therapies in these populations.